Evidence map›Paper›PMID 39023263›Full record

ArticleAntimicrobial agents and chemotherapy2024

Cimicifugin, a broad-spectrum inhibitor of

Prajna Parimita Kar, Prasanna Babu Araveti, Kanika Saxena, Atlanta Borah, Puran Sijwali, Anand Srivastava

Erratum issuedAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Prajna Parimita KarBRIC-NIAB (National Institute of Animal Biotechnology), Hyderabad, India.
Prasanna Babu AravetiBRIC-NIAB (National Institute of Animal Biotechnology), Hyderabad, India.
Kanika SaxenaCSIR-CCMB (Center for Cellular and Molecular Biology), Hyderabad, India.
Atlanta BorahBRIC-NIAB (National Institute of Animal Biotechnology), Hyderabad, India.
Puran SijwaliCSIR-CCMB (Center for Cellular and Molecular Biology), Hyderabad, India.ORCID 0000-0002-6956-6454
Anand SrivastavaBRIC-NIAB (National Institute of Animal Biotechnology), Hyderabad, India.ORCID 0000-0002-2031-4643

Funding

Department of Science and technology (DST)-Inspire fellowship IF160609Department of Science and Technology (DST) Inspire fellowship IF160249DST | Science and Engineering Research Board (SERB) CRG/2021/003634Science and Engineering Research Board (SERB) CRG/2021/003634
6 · The paper itself

Abstract

Cyclin-dependent kinase 7 is an attractive therapeutic target for the treatment of cancers, and a previous report suggested that

Indexed as

AntimalarialsApoptosisCyclin-Dependent KinasesPlasmodium falciparumTheileria annulataAnimalsAutophagyCattleCell LineHumansAntimalarialsCyclin-Dependent KinasesapicomplexaCDK7cyclin-dependent kinaseskinasesPlasmodium falciparumTheileria annulata

Identifiers

PMID39023263
PMCPMC11304743

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.